Virginia Parks

498 total citations
24 papers, 365 citations indexed

About

Virginia Parks is a scholar working on Surgery, Small Animals and Pharmacology. According to data from OpenAlex, Virginia Parks has authored 24 papers receiving a total of 365 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Surgery, 4 papers in Small Animals and 4 papers in Pharmacology. Recurrent topics in Virginia Parks's work include Helminth infection and control (4 papers), Renal Transplantation Outcomes and Treatments (3 papers) and Attention Deficit Hyperactivity Disorder (2 papers). Virginia Parks is often cited by papers focused on Helminth infection and control (4 papers), Renal Transplantation Outcomes and Treatments (3 papers) and Attention Deficit Hyperactivity Disorder (2 papers). Virginia Parks collaborates with scholars based in United States, France and Canada. Virginia Parks's co-authors include Alain Patat, Joan Korth‐Bradley, Kyle Matschke, Lawrence Fleckenstein, Honghui Zhou, Ian Gourley, Stephan Chalon, Anna Plotka, Steven Troy and Géraldine M. Ferron and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Virginia Parks

24 papers receiving 346 citations

Peers

Countries citing papers authored by Virginia Parks

Since Specialization

Citations

This map shows the geographic impact of Virginia Parks's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Virginia Parks with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Virginia Parks more than expected).

Fields of papers citing papers by Virginia Parks

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Virginia Parks. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Virginia Parks. The network helps show where Virginia Parks may publish in the future.

Co-authorship network of co-authors of Virginia Parks

This figure shows the co-authorship network connecting the top 25 collaborators of Virginia Parks. A scholar is included among the top collaborators of Virginia Parks based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Virginia Parks. Virginia Parks is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Fit‐for‐Purpose Biometric Monitoring Technologies: Leveraging the Laboratory Biomarker Experience 2020 ·Clinical and Translational Science ·Alan Godfrey, Benjamin Vandendriessche, Jessie P. Bakker, Cheryl Fitzer‐Attas, (unknown), M. Hobbs, Qi Liu, Carrie A. Northcott, Virginia Parks, William A. Wood, Vadim Zipunnikov, John A. Wagner, Elena S. Izmailova	37
2	Effect of anagrelide on cardiac repolarization in healthy volunteers: a randomized, double‐blind, placebo‐ and positive‐controlled, thorough QT study 2014 ·Pharmacology Research & Perspectives ·Steven Troy, Virginia Parks, (unknown), (unknown), Daniel B. Goodman, (unknown), Martin Armstrong, Patrick Martin	1
3	Effect of moxidectin on CYP3A4 activity as evaluated by oral midazolam pharmacokinetics in healthy subjects 2013 ·Clinical Pharmacology in Drug Development ·Joan Korth‐Bradley, Virginia Parks, Frank Wagner, Stephan Chalon, Ian Gourley, Kyle Matschke, (unknown), Sharon L. Ripp, Lawrence Fleckenstein	15
4	The evaluation of potential pharmacokinetic interaction between sirolimus and tacrolimus in healthy volunteers 2012 ·European Journal of Clinical Pharmacology ·Michael A. Tortorici, Virginia Parks, Kyle Matschke, Joan Korth‐Bradley, Alain Patat	7
5	Relative Bioavailability of Liquid and Tablet Formulations of the Antiparasitic Moxidectin 2012 ·Clinical Pharmacology in Drug Development ·Joan Korth‐Bradley, Virginia Parks, Alain Patat, Kyle Matschke, Philip R. Mayer, Lawrence Fleckenstein	31
6	Concomitant blockade of 5-HT1A receptor and 5-HT transporter: Use of the Hunter Serotonin Toxicity Criteria in a clinical pharmacology study 2011 ·European Neuropsychopharmacology ·Virginia Parks, (unknown), (unknown), Anna Plotka, Lee E. Schechter, (unknown), Sylvie Chalon	5
7	Excretion of Moxidectin into Breast Milk and Pharmacokinetics in Healthy Lactating Women 2011 ·Antimicrobial Agents and Chemotherapy ·Joan Korth‐Bradley, Virginia Parks, Stephan Chalon, Ian Gourley, Kyle Matschke, (unknown), Philip Bryson, Lawrence Fleckenstein	36
8	Safety, tolerability, pharmacokinetics and pharmacodynamics of ascending single and multiple doses of lecozotan in healthy young and elderly subjects 2009 ·British Journal of Clinical Pharmacology ·Alain Patat, Virginia Parks, Sangeeta Raje, Anna Plotka, D Chassard, F. Le Coz	17
9	Pharmacokinetics of Sirolimus (Rapamycin) in Subjects With Severe Hepatic Impairment 2008 ·The Journal of Clinical Pharmacology ·(unknown), Alain Patat, Virginia Parks, Romain Moirand, Kyle Matschke	16
10	A Positron Emission Tomography Study to Assess Binding of Lecozotan, a Novel 5-Hydroxytryptamine-1A Silent Antagonist, to Brain 5-HT1A Receptors in Healthy Young and Elderly Subjects, and in Patients With Alzheimer's Disease 2007 ·Clinical Pharmacology & Therapeutics ·(unknown), Alain Patat, Virginia Parks, (unknown), Anna Plotka, (unknown), Bengt Långström	26
11	Lecozotan Hydrochloride 2007 ·Drugs of the Future ·Wayne E. Childers, (unknown), Magid Abou‐Gharbia, (unknown), Virginia Parks, (unknown), Lee E. Schechter	4
12	PIII-39Safety, tolerability and pharmacokinetics (PK) of multiple doses of lecozotan, a novel 5HT1A antagonist, in healthy elderly subjects 2006 ·Clinical Pharmacology & Therapeutics ·Virginia Parks, (unknown), Alain Patat, Anna Plotka, B Astruc, D Chassard	1
13	Safety, pharmacokinetics (<>Pk) and pharmacodynamics (PD) of ascending single oral doses of sustained-release desvenlafaxine succinate (DVS-SR) in healthy subjects 2005 ·Clinical Pharmacology & Therapeutics ·Virginia Parks, Alain Patat, (unknown), Steven Troy, (unknown)	5
14	Safety, pharmacokinetics (PK) and pharmacodynamics (PD) of ascending single doses of desvenlafaxine (DVS-233 SR) in healthy subjects 2005 ·Clinical Pharmacology & Therapeutics ·Virginia Parks, Alain Patat, (unknown), Vernon D. Parker, (unknown)	6
15	Absence of a Clinically Relevant Interaction Between Etanercept and Digoxin 2004 ·The Journal of Clinical Pharmacology ·Honghui Zhou, Virginia Parks, Alain Patat, F. Le Coz, Donna Simcoe, Joan Korth‐Bradley	24
16	Absence of a Pharmacokinetic Interaction between Etanercept and Warfarin 2004 ·The Journal of Clinical Pharmacology ·Honghui Zhou, Alain Patat, Virginia Parks, Mary Buckwalter, Déborah Metzger, Joan Korth‐Bradley	31
17	Lack of pharmacokinetic interaction between retigabine and phenobarbitone at steady‐state in healthy subjects 2003 ·British Journal of Clinical Pharmacology ·Géraldine M. Ferron, Alain Patat, Virginia Parks, Paul Rolan, Steven Troy	34
18	Lack of Pharmacokinetic Interaction Co‐Administered of Sirolimus and Tacrolimus 2003 ·Clinical Pharmacology & Therapeutics ·Alain Patat, James J. Zimmerman, Virginia Parks, (unknown)	14
19	Open-label evaluation of once-daily venlafaxine XR in depressed outpatients 1998 ·European Neuropsychopharmacology ·D. Hackett, Virginia Parks, Eliseo Salinas	1
20	SYMPATHOMIMETIC DRUGS IN ORTHOSTATIC HYPOTENSION 1961 ·The Lancet ·Virginia Parks	23

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact